SCHEMBL5209911

SCHEMBL5209911

C=CCc1cc(C2CCCCC2)ccc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.53
GABRB2 P47870 3/20 0.53
ACMSD Q8TDX5 2/20 0.49
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
POLB P06746 2/20 0.46
MEN1 O00255 2/20 0.43
GAA P10253 2/20 0.43
MAPT P10636 2/20 0.43
CNR1 P21554 2/20 0.43
CNR2 P34972 2/20 0.43
KMT2A Q03164 2/20 0.43
ALOX5 P09917 1/20 0.43
GABRB1 P18505 1/20 0.43
RXRA P19793 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRA2 P47869 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21630425 1.00 GABRA1 (0.53) GABRA1GABRB2ACMSDALDH1A1HPGD
SCHEMBL7148942 0.86 GABRA1 (0.51) GABRA1GABRB2ACMSDALDH1A1HPGD
SCHEMBL7147579 0.86 GABRA1 (0.51) GABRA1GABRB2ACMSDALDH1A1HPGD
SCHEMBL9614879 0.84 GABRA1 (0.49) GABRA1GABRB2ACMSDALDH1A1HPGD
SCHEMBL9614880 0.84 GABRA1 (0.49) GABRA1GABRB2ACMSDALDH1A1HPGD
SCHEMBL28541380 0.82 ACMSD (0.56) ACMSDHPGDLMNAHTTMEN1
SCHEMBL9617330 0.80 GABRA1 (0.45) GABRA1GABRB2ACMSDALDH1A1HPGD
SCHEMBL27956345 0.80 ACMSD (0.54) ACMSDHDAC4HDAC2HDAC8KMO
SCHEMBL11595671 0.80 ACMSD (0.54) ACMSDHPGDLMNAHTTMEN1
SCHEMBL11161163 0.79 ACMSD (0.57) ACMSDHDAC4HDAC2HDAC8KMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115232585-B Single-component epoxy resin composition resistant to wet-hot hydrolysis, and preparation method and application thereof 同济大学 2023-11-24 CN claimed
CN-115093567-B Ultraviolet light curing resin composition based on thiol-ene reaction, and preparation method and application thereof 同济大学 2023-08-04 CN claimed
CN-115232585-A Single-component epoxy resin composition resistant to wet heat hydrolysis and preparation method and application thereof 同济大学 2022-10-25 CN claimed
CN-115232259-A Wet-heat hydrolysis-resistant dual-curing resin composition and preparation method and application thereof 同济大学 2022-10-25 CN claimed
CN-115093567-A Ultraviolet curing resin composition based on thiol-ene reaction and preparation method and application thereof 同济大学 2022-09-23 CN claimed
CN-115232259-B Moisture-heat hydrolysis resistant dual-curing resin composition and preparation method and application thereof 同济大学 2024-02-27 CN disclosed
CN-115232585-B Single-component epoxy resin composition resistant to wet-hot hydrolysis, and preparation method and application thereof 同济大学 2023-11-24 CN disclosed
CN-115093567-B Ultraviolet light curing resin composition based on thiol-ene reaction, and preparation method and application thereof 同济大学 2023-08-04 CN disclosed
CN-115232585-A Single-component epoxy resin composition resistant to wet heat hydrolysis and preparation method and application thereof 同济大学 2022-10-25 CN disclosed
CN-115232259-A Wet-heat hydrolysis-resistant dual-curing resin composition and preparation method and application thereof 同济大学 2022-10-25 CN disclosed
CN-115093567-A Ultraviolet curing resin composition based on thiol-ene reaction and preparation method and application thereof 同济大学 2022-09-23 CN disclosed
EP-1194147-B1 ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES MERCK & CO INC (US) 2007-01-10 EP disclosed
US-6670474-B2 Such as bis-1,2-(2-(2,3-epoxypropyl)phenoxy)ethane; chemical intermediates for formation of epoxy resins PEWS R GARTH (US) 2003-12-30 US disclosed
US-20020151731-A1 Novel epoxide derivatives of allylarylphenols PEWS R GARTH (US) 2002-10-17 US disclosed
US-6465497-B2 SUBSTITUTED 5-ARYL-2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES; AGONISTS OF PPAR (PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR); USEFUL TREATING DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, AND OBESITY MERCK & CO., INC. 2002-10-15 US disclosed
EP-1194147-A4 ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES MERCK & CO INC (US) 2002-10-09 EP disclosed
US-6380191-B1 FOR TREATMENT, CONTROL OR PREVENTION OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA (INCLUDING HYPERCHOLESTEROLEMIA AND HYPERTRIGLYCERIDEMIA), ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS MERCK & CO. INC. 2002-04-30 US disclosed
EP-1194147-A1 ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES Merck & Co., Inc. (US) 2002-04-10 EP disclosed
US-20020037911-A1 Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity MERCK & CO., INC. 2002-03-28 US disclosed
WO-2000078313-A1 ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES MERCK & CO., INC. (US) 2000-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037911-A1 Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity PPARD, PPARA, PPARG GABRA1 979/4885GABRB2 812/4885ACMSD 3109/4885
US-20020151731-A1 Novel epoxide derivatives of allylarylphenols EPHX2, CBR3, CYP4X1 GABRA1 2014/4885GABRB2 2055/4885ACMSD 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.